ライフサイエンスコーパス: strongyloidiasis

1 ferred for the treatment of non-disseminated strongyloidiasis.

2 nnovative serodiagnosis method for the human strongyloidiasis.

3 ved drug efficacies against trichuriasis and strongyloidiasis.

4 f malabsorption from severe gastrointestinal strongyloidiasis.

5 use of DAF-12 ligands to treat disseminated strongyloidiasis.

6 tate hyperinfection and, hence, disseminated strongyloidiasis.

7 l in diagnostic and epidemiologic studies of strongyloidiasis.

8 were common among hospitalized patients with strongyloidiasis.

9 re present in 41.3% of hospitalizations with strongyloidiasis.

10 sed to identify risk factors associated with strongyloidiasis.

11 c approaches for treating parasitism such as Strongyloidiasis.

12 low median income were also associated with strongyloidiasis.

13 n RR of mortality and regional prevalence of strongyloidiasis.

14 e dose for the treatment of non-disseminated strongyloidiasis.

15 7%), malaria (7%), schistosomiasis (6%), and strongyloidiasis (5%); 5% were reported healthy.

16 Strongyloidiasis affects migrants from all global region

17 uding CSU might be a quite common symptom of strongyloidiasis and blastocystosis.

18 sian analyses using prevalence estimation of strongyloidiasis and onchocerciasis as two relevant exam

19 Global migration from regions where strongyloidiasis and schistosomiasis are endemic to non-

20 Pooled estimates of the prevalence of strongyloidiasis and schistosomiasis by stool or urine m

21 did a systematic review and meta-analysis of strongyloidiasis and schistosomiasis prevalence among mi

22 hmaniasis, toxoplasmosis, cryptosporidiosis, strongyloidiasis, and filariasis) as well as travelers'

23 Geographic distribution of strongyloidiasis associated hospitalization was assessed

24 urveillance data, especially data evaluating strongyloidiasis associated with hospitalization, are la

25 Strongyloidiasis-associated hospitalization is rare in t

26 ital death occurred in 7.8% of patients with strongyloidiasis-associated hospitalization.

27 ther patient also had complete resolution of strongyloidiasis, but required a course of parenteral iv

28 Because diagnosis of strongyloidiasis by stool examination is unreliable and

29 Strongyloidiasis can cause devastating morbidity and dea

30 tified 6931 hospitalizations associated with strongyloidiasis during the study period (11.8 per milli

31 The strongyloidiasis example addresses the problem of parasi

32 and HIV/AIDS were reported from all regions, strongyloidiasis from most regions, and chronic hepatiti

33 explain the notable absence of disseminated strongyloidiasis in advanced HIV disease.

34 Identification of reliable biomarkers for strongyloidiasis in immunosuppressed patients is critica

35 isease and impaired response to treatment of strongyloidiasis in some HTLV-1-infected persons.

36 es - ascariasis, trichuriasis, hookworm, and strongyloidiasis - in addition to the intestinal and liv

37 ar epidemiological surveillance for zoonotic strongyloidiasis is confounded by a genus-specific TaqMa

38 ding visceral leishmaniasis, Chagas disease, strongyloidiasis, malaria, schistosomiasis, histoplasmos

39 ween the results of groups with low and high strongyloidiasis prevalence (chi21 = 4.79; P = .03).

40 r trials (33%) took place in regions of high strongyloidiasis prevalence and 8 (67%) trials took plac

41 ivermectin trials in regions of high vs low strongyloidiasis prevalence and correlation coefficient

42 alysis of 12 trials including 3901 patients, strongyloidiasis prevalence was found to interact with t

43 ls that took place in areas of high regional strongyloidiasis prevalence were associated with a signi

44 Differences by strongyloidiasis prevalence were estimated using subgrou

45 als that took place in areas of low regional strongyloidiasis prevalence were not associated with a s

46 8 (67%) trials took place in regions of low strongyloidiasis prevalence.

47 5% CI, 0.87%-62.25%) for each 5% increase in strongyloidiasis prevalence.

48 sis (TB), hepatitis B, hepatitis C, malaria, strongyloidiasis, schistosomiasis, other intestinal para

49 Pooled strongyloidiasis seroprevalence was 12.2% (95% CI 9.0-15

50 ompromised population at high risk of severe strongyloidiasis syndromes.

51 rent but limited drug of choice for treating strongyloidiasis, the combinatorial effects of the two d

52 This study suggests that, in SOT patients, strongyloidiasis triggers both eosinophilia and eosinoph

53 ction in serum samples from individuals with strongyloidiasis using a sandwich enzyme-linked immunoso

54 a population-based retrospective analysis on strongyloidiasis using the National Inpatient Sample fro

55 The rate of strongyloidiasis was highest in the Northeast US region,

56 mong patients with COVID-19 in regions where strongyloidiasis was not endemic.

57 s expressing Th1, Th2, and Th17 cytokines in strongyloidiasis, we compared the frequency (Fo) of thes